Ligand Pharmaceuticals CEO John Higgins Sells 10,000 Shares (LGND)
Ligand Pharmaceuticals (NASDAQ:LGND) CEO John Higgins sold 10,000 shares of the stock in a transaction that occurred on Friday, October 18th. The shares were sold at an average price of $55.00, for a total transaction of $550,000.00. Following the transaction, the chief executive officer now directly owns 117,099 shares of the company’s stock, valued at approximately $6,440,445. The transaction was disclosed in a legal filing with the SEC, which is available at this link.
Ligand Pharmaceuticals (NASDAQ:LGND) traded up 0.39% during mid-day trading on Tuesday, hitting $54.47. The stock had a trading volume of 228,837 shares. Ligand Pharmaceuticals has a 52-week low of $14.75 and a 52-week high of $50.85. The stock’s 50-day moving average is $45.76 and its 200-day moving average is $34.10. The company has a market cap of $1.113 billion and a price-to-earnings ratio of 128.88.
Ligand Pharmaceuticals (NASDAQ:LGND) last announced its earnings results on Thursday, August 1st. The company reported $0.07 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.06 by $0.01. The company had revenue of $9.58 million for the quarter, compared to the consensus estimate of $9.48 million. Ligand Pharmaceuticals’s revenue was up 66.8% compared to the same quarter last year. On average, analysts predict that Ligand Pharmaceuticals will post $0.50 earnings per share for the current fiscal year.
A number of analysts have recently weighed in on LGND shares. Analysts at Cantor Fitzgerald reiterated a “sell” rating on shares of Ligand Pharmaceuticals in a research note to investors on Wednesday, September 11th. They now have a $37.00 price target on the stock. Separately, analysts at MLV Capital raised their price target on shares of Ligand Pharmaceuticals to $62.00 in a research note to investors on Wednesday, September 11th. They now have a “buy” rating on the stock. Finally, analysts at Summer Street raised their price target on shares of Ligand Pharmaceuticals from $36.00 to $64.00 in a research note to investors on Friday, August 2nd. They now have a “buy” rating on the stock. One research analyst has rated the stock with a sell rating, one has given a hold rating and five have given a buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus target price of $55.50.
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) is a biotechnology company that operates with a business model focused on developing or acquiring assets.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.